North America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Cha

North America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)

The North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030. Upsurge in Geriatric Population Fuels North America Sarcopenia Treatment Market The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. Also, according to the 2020 Census, the population of US 65 and older increased about five times faster than the total population during the 100 years between 1920 and 2020. In 2020, the number of older populations reached 55.8 million, or 16.8% of the total population of the US. Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth. North America Sarcopenia Treatment Market Overview The sarcopenia treatment market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. The sarcopenia treatment market growth in North America is attributed to the rising adoption of nutraceutical supplements for the treatment. In addition, the surging prevalence of orthopedic disorders with the increasing number of cases of vitamin B12 and vitamin D deficiency in the geriatric population fuels the market in this region. Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia. Additionally, a 10% decrease in the loss of skeletal muscle can prevent the possible comorbidity of sarcopenia and save around US$ 1 billion in annual US medical care expenses. North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million) North America Sarcopenia Treatment Market Segmentation The North America sarcopenia treatment market is categorized into treatment type, distribution channel, and country. Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest North America sarcopenia treatment market share in 2022. In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest North America sarcopenia treatment market share in 2022. By country, the North America sarcopenia treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America sarcopenia treatment market share in 2022. Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are some of the leading companies operating in the North America sarcopenia treatment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America sarcopenia treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America sarcopenia treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America sarcopenia treatment market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.